**Practice Alert for the Perioperative Management of Patients with Coronary Artery Stents**

_A Report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters_

PRACTICE Alerts are consensus-based reports that address specific aspects of patient management, patient care, and patient safety.

This Practice Alert reviews published recommendations that address the perioperative management of surgical patients with recently implanted coronary artery stents. The intent of the Alert is to provide the anesthesiologist with information about (1) the increased risk of perioperative myocardial infarction and death in these patients and (2) the relation between antiplatelet therapy and acute perioperative stent thrombosis.

A major concern after successful coronary artery stent placement is the potential for acute stent thrombosis, with subsequent myocardial infarction and death. To prevent stent thrombosis in the nonsurgical setting, cardiologists typically recommend dual antiplatelet therapy after coronary stent placement. Dual therapy typically consists of a combination of aspirin and thienopyridine.

**Premature discontinuation** of dual antiplatelet therapy in patients with coronary artery stents who are scheduled to undergo surgery increases the risk of stent thrombosis, myocardial infarction, and death. This opinion was issued as a 2007 Science Advisory by the American Heart Association (AHA), American College of Cardiology (ACC), Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association. This opinion is also supported by the ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery.

**When Surgery Can Be Postponed**


A. The 2007 Science Advisory recommends that elective procedures for which there is significant risk of perioperative or postoperative bleeding should be deferred until an appropriate course of thienopyridine therapy has been completed. The course of thienopyridine therapy associated with this recommendation is as follows:

- **Bare-metal stents:** minimum of 1 month
- **Drug-eluting stents:** 12 months after implantation if the patient is not at high risk of bleeding

B. The 2007 ACC/AHA Guidelines do not recommend elective noncardiac surgery within the following time periods after stent implantation when thienopyridine therapy or aspirin and thienopyridine therapy need to be discontinued perioperatively:

- **Bare-metal stents:** 4–6 weeks
- **Drug-eluting stents:** 12 months

**When Surgery Cannot Be Postponed**

If the course of thienopyridine therapy must be interrupted in patients with new coronary stents, both the 2007 Science Advisory and the 2007 ACC/AHA Guidelines recommend that aspirin therapy be continued throughout the perioperative period, if possible. In addition, both the 2007 Science Advisory and the 2007 ACC/AHA Guidelines recommend that thienopyridine therapy should be restarted as soon as possible after the procedure.

**Other Considerations**

Anticoagulants and antiplatelet agents with short half-lives have been suggested as a way to bridge the gap between discontinuation of antiplatelet therapy and surgery. Both the 2007 Science Advisory and the 2007 ACC/AHA Guidelines considered the current evidence for risk and benefits and jointly concluded that there is no evidence that warfarin, antithrombotics, or glycoprotein IIIb/IIIa agents reduce the risk of stent thrombosis after discontinuation of oral antiplatelet agents.

In addition, the 2007 ACC/AHA Guidelines recommend that consideration should be given to continuing dual antiplatelet therapy perioperatively beyond the recommended time frame in any patient at high risk for stent thrombosis. Even after thienopyridine has been
Premature discontinuation of dual antiplatelet therapy in patients with new coronary stents is associated with an increased risk of life-threatening stent thrombosis in the perioperative period. The time period for this risk is 4–6 weeks for bare-metal stents and 12 months for drug-eluting stents.

Recommendations about the timing of elective surgery in patients with new coronary stents are given in slightly different ways by the 2007 Science Advisory and the 2007 ACC/AHA Guidelines. The 2007 Science Advisory states that elective procedures for which there is a significant risk of perioperative or postoperative bleeding should be deferred until patients have completed an appropriate course of thienopyridine therapy. The 2007 ACC/AHA Guidelines state that elective noncardiac surgery is not recommended when thienopyridine therapy or thienopyridine and aspirin therapy needs to be continued during the perioperative period. For both recommendations, the prescribed period of thienopyridine therapy or thienopyridine and aspirin therapy is a minimum of 1 month or 4–6 weeks for bare-metal stents and 12 months for drug-eluting stents.

If surgery cannot be deferred and thienopyridine therapy must be interrupted in patients with new coronary stents, aspirin should be continued if possible. The thienopyridine should be restarted as soon as possible after the surgical procedure.

Consideration should be given to continuing dual antiplatelet therapy perioperatively beyond the recommended time frame in any patient at high risk for stent thrombosis. Even after thienopyridine has been discontinued, serious consideration should be given to continuation of aspirin antiplatelet therapy perioperatively in any patient with a drug-eluting stent.

References